These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 17040923

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K, Tanaka K, Yamamichi F, Shirakawa T, Miyake H, Fujisawa M.
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [Abstract] [Full Text] [Related]

  • 3. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC, Seol SY, Gurung M, Jin JS, Choi CH, Kim J, Lee YC, Cho DT, Lee JC.
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R, Sato K, Kumita W, Inami N, Nishiyama H, Okamura N, Moriya K, Koike K.
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [Abstract] [Full Text] [Related]

  • 8. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H.
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of resistance to fluoroquinolones and carbapenems in Pseudomonas putida.
    Horii T, Muramatsu H, Iinuma Y.
    J Antimicrob Chemother; 2005 Oct; 56(4):643-7. PubMed ID: 16046469
    [Abstract] [Full Text] [Related]

  • 10. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK, Nair S, Wain J.
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [Abstract] [Full Text] [Related]

  • 11. Mutant-prevention concentrations of enrofloxacin for Escherichia coli isolates from chickens.
    Li Q, Bi X, Diao Y, Deng X.
    Am J Vet Res; 2007 Aug; 68(8):812-5. PubMed ID: 17669019
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rapid and sensitive detection of fluoroquinolone-resistant Escherichia coli from urine samples using a genotyping DNA microarray.
    Yu X, Susa M, Weile J, Knabbe C, Schmid RD, Bachmann TT.
    Int J Med Microbiol; 2007 Oct; 297(6):417-29. PubMed ID: 17482874
    [Abstract] [Full Text] [Related]

  • 15. A survey of plasmid-mediated fluoroquinolone resistance genes from Escherichia coli isolates and their dissemination in Shandong, China.
    Xia LN, Li L, Wu CM, Liu YQ, Tao XQ, Dai L, Qi YH, Lu LM, Shen JZ.
    Foodborne Pathog Dis; 2010 Feb; 7(2):207-15. PubMed ID: 19911944
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M, Higa F, Nakasone C, Shinzato T, Akamine M, Haranaga S, Tateyama M, Nakasone I, Yamane N, Fujita J.
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [Abstract] [Full Text] [Related]

  • 17. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N, Nielsen L, Jakobsen L, Stegger M, Hansen LH, Frimodt-Møller N.
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Characteristics of Romanian fluoroquinolone-resistant human clinical Escherichia coli isolates.
    Usein CR, Tatu-Chiţoiu D, Nica M, Ciontea SA, Palade AM, Condei M, Damian M.
    Roum Arch Microbiol Immunol; 2008 Sep; 67(1-2):23-9. PubMed ID: 19284163
    [Abstract] [Full Text] [Related]

  • 20. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
    Zhao X, Quinn B, Kerns R, Drlica K.
    J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.